Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECIST

This Viewpoint evaluates the present relevance of Response Evaluation Criteria in Solid Tumors (RECIST) as cancer therapeutics have evolved beyond cytotoxic chemotherapy in assessing treatment outcomes.

Corresponding Author: Chadi Nabhan, MD, MBA, 1950 Corporate Way, Ste 12489, Anaheim, CA 92801 (cnabhan1968@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.